Dimerix have updated their corporate fact sheet
You can view the fact sheet here
Baker Young Stockbrokers have initiated coverage of Dimerix Limited.
The research report is available here:
Dimerix Limited (ASX: DXB), is pleased to announce that it has received ethics committee approval for a study in healthy volunteers to determine the pharmacokinetic properties of the novel extended release propagermanium tablet to be used in the Company’s DMX-200 Phase 2b trial in Chronic Kidney Disease.
Read the full release […]
We are very pleased to announce the appointment of a Medical Advisory Board (MAB) to help guide the Company’s DMX-200 clinical program.
The Medical Advisory Board will provide clinical and strategic input into the Company’s lead program, DMX-200 in Chronic Kidney Disease and will provide guidance to the Company as it shapes and progresses its DMX-200 […]
Dimerix (ASX:DXB) is pleased to announce the receipt of a Research and Development (R&D) Tax Incentive refund of $545,771 for the 2016/2017 financial year.
The refund relates to eligible expenditure on the company’s lead program, DMX-200, which has just completed a successful Phase 2a trial, meeting its primary endpoint (safety and tolerability) and showing signals of […]
Read our September 2017 Shareholder Update here
Dimerix CEO Kathy Harrison is pleased to be speaking alongside a great collection of other biotech companies at the Western Australian AusBiotech Broker Meets Biotech event today.
Date: Wednesday 13 September 2017
Time: 1:00pm arrival for a 1:30pm start
Venue: Parmelia Hilton Perth
14 Mill Street